Hence, the efficacy of dupilumab in inhibiting the pathobiologic mechanisms underlying type 2 inflammation, strongly dependent on IL-4 and IL-13 actions, explains the extension of the therapeutic effects of this monoclonal antibody to both asthma and nasal polyposis in our patients. Here, IL4 is linked to asthma.